Creation of a CF-specific antibiotic spectrum index (ASI) as an antimicrobial stewardship initiative

Antibiotics are routinely included in the treatment of cystic fibrosis (CF)-related pulmonary exacerbations (PEx) despite limited data to guide optimal selection. Unsurprisingly, this dearth of evidence has led to substantial variability in antibiotic choice[1,2]. Antibiotics are frequently selected based on prior successful PEx treatment regimens or on prior respiratory culture and susceptibility results. Although antibiotic use among people with CF (PwCF) has been associated with improved clinical outcomes[3,4], there are growing concerns related to antimicrobial resistance and other important antibiotic-related adverse effects, including ototoxicity and nephrotoxicity[5 –7].
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Tags: Short Communication Source Type: research